Cheng Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cheng Huang has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Hui Ma
Department of Rehabilitation Medicine, Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
9 shared publicationsJiuhong You
Department of Rehabilitation Medicine, Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
9 shared publicationsMei Zhou
Department of Rehabilitation Medicine, West China Hospital Sichuan University Chengdu Sichuan China
9 shared publicationsXinxin Chen
Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University
9 shared publicationsDan Li
Department of Rehabilitation Medicine, Center for High Altitude Medicine, West China Hospital, Sichuan University
6 shared publicationsJiao Luo
Department of Rehabilitation Medicine, Center for High Altitude Medicine, West China Hospital, Sichuan University
4 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1826010
Combined hyperbaric oxygen and repetitive transcranial magnetic stimulation for vascular cognitive impairment: a randomized controlled trial
Background: Effective rehabilitation strategies for vascular cognitive impairment (VCI) still remain limited. This study was aimed to explore the clinical efficacy and related mechanisms of hyperbaric oxygen therapy (HBOT) combined with repetitive transcranial magnetic stimulation (rTMS) for VCI. Methods: 72 participants were recruited and randomly assigned to the control, HBOT, rTMS, and Combined (HBOT combined with rTMS) groups. The primary outcome measures were the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE), while the secondary outcome measures comprised the Modified Barthel Index (MBI), the Self-rating Anxiety Scale (SAS), and the Self-Rating Depression Scale (SDS). The concentration of oxygenated hemoglobin (HbO 2 ) in the cerebral cortex was measured by near-infrared spectroscopy (fNIRS). These indicators were measured at the baseline (T1) and 3 weeks after the intervention (T2). Results: After treatment, the significant improvements in MoCA, MMSE, and MBI scores, and the reductions in SAS and SDS scores were observed across all groups (all p < 0.05). Regarding the primary outcomes, the combined group showed significantly greater improvement in MoCA and MMSE scores compared to each of the other three groups ( p < all 0.05). For the secondary outcomes, the combined treatment group showed significantly greater improvement in MBI scores only than the control group ( p < 0.05), and no significant inter-group differences were observed in the changes of SAS or SDS scores before and after treatment (all p > 0.05). Additionally, fNIRS analysis following FDR correction showed that CH9 and CH45 channels had statistically significant differences in HbO 2 after treatment (all p < 0.05), though a sensitivity analysis suggested these findings may be partially influenced by physiological noise. Conclusion: Combined HBOT and rTMS therapy demonstrates superior efficacy in improving cognitive function which may be mediated by the primary somatosensory cortex and primary motor cortex of the brain. However, the combined regimen did not yield greater improvement in daily function or mood. Combined HBOT + rTMS is a promising cognitive rehabilitation strategy in the treatment of VCI. Clinical trial registration: https://www.chictr.org.cn/showproj.html?proj=190934 , Identifier ChiCTR2300068242.
- 18 August 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1826010
Open AccessCombined hyperbaric oxygen and repetitive transcranial magnetic stimulation for vascular cognitive impairment: a randomized controlled trial
Background: Effective rehabilitation strategies for vascular cognitive impairment (VCI) still remain limited. This study was aimed to explore the clinical efficacy and related mechanisms of hyperbaric oxygen therapy (HBOT) combined with repetitive transcranial magnetic stimulation (rTMS) for VCI. Methods: 72 participants were recruited and randomly assigned to the control, HBOT, rTMS, and Combined (HBOT combined with rTMS) groups. The primary outcome measures were the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE), while the secondary outcome measures comprised the Modified Barthel Index (MBI), the Self-rating Anxiety Scale (SAS), and the Self-Rating Depression Scale (SDS). The concentration of oxygenated hemoglobin (HbO 2 ) in the cerebral cortex was measured by near-infrared spectroscopy (fNIRS). These indicators were measured at the baseline (T1) and 3 weeks after the intervention (T2). Results: After treatment, the significant improvements in MoCA, MMSE, and MBI scores, and the reductions in SAS and SDS scores were observed across all groups (all p < 0.05). Regarding the primary outcomes, the combined group showed significantly greater improvement in MoCA and MMSE scores compared to each of the other three groups ( p < all 0.05). For the secondary outcomes, the combined treatment group showed significantly greater improvement in MBI scores only than the control group ( p < 0.05), and no significant inter-group differences were observed in the changes of SAS or SDS scores before and after treatment (all p > 0.05). Additionally, fNIRS analysis following FDR correction showed that CH9 and CH45 channels had statistically significant differences in HbO 2 after treatment (all p < 0.05), though a sensitivity analysis suggested these findings may be partially influenced by physiological noise. Conclusion: Combined HBOT and rTMS therapy demonstrates superior efficacy in improving cognitive function which may be mediated by the primary somatosensory cortex and primary motor cortex of the brain. However, the combined regimen did not yield greater improvement in daily function or mood. Combined HBOT + rTMS is a promising cognitive rehabilitation strategy in the treatment of VCI. Clinical trial registration: https://www.chictr.org.cn/showproj.html?proj=190934 , Identifier ChiCTR2300068242.
- Open Access
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1860690
The influence of refined enteral nutrition intervention on nutritional status and feeding intolerance in critically ill stroke patients
Background: Critically ill stroke patients frequently experience dysphagia, posing challenges to adequate nutrient intake. Furthermore, these patients often remain in a prolonged state of high stress, hypermetabolism, and reduced immunity. While early enteral nutritional support is crucial, feeding intolerance remains a prevalent issue. This study evaluates the real-world impact of a refined enteral nutrition (EN) intervention on EN outcomes. Objective: To investigate the effect of a refined enteral nutrition intervention on nutritional status and feeding intolerance in critically ill stroke patients. Methods: This quasi-experimental study employed a pre-post design. The control group ( n = 81; January–December 2022) was retrospectively enrolled, and the intervention group ( n = 81; January–December 2023) was prospectively enrolled. The Control group received routine nutrition management, and the Intervention group received refined enteral nutrition management. Primary outcomes assessed included: (1) Nutritional markers: Serum albumin, hemoglobin, triceps skinfold thickness (non-paralyzed side), mid-upper arm circumference (non-paralyzed side); (2) EN intolerance incidence: Diarrhea (≥3 stools/day), vomiting, abdominal distension, elevated gastric residual volume (≥250 mL); (3) Disease severity: APACHE II score. Energy and protein targets were calculated individually (25–30 kcal/kg/day and 1.2–2.0 g/kg/day). Achievement of ≥70% of both targets was considered adequate. (4) Nutritional Risk Screening (NRS2002) and hospital length of stay were also recorded. Results: Post-intervention albumin levels were significantly higher in the Intervention group (40.69 ± 1.88 g/L) compared to the Control group (38.92 ± 1.21 g/L; t = −7.147, p < 0.001), mean difference 1.77 g/L [95% CI: 1.29–2.25], Cohen’s d = 1.12, with comparable baseline values (36.97 ± 2.34 vs. 36.81 ± 1.67 g/L; p = 0.056). Post-intervention hemoglobin levels were also significantly higher in the Intervention group (114.40 ± 8.00 g/L vs. 110.57 ± 6.52 g/L; t = −3.337, p = 0.001), despite comparable baseline values (97.37 ± 9.89 vs. 99.77 ± 5.92 g/L; t = 1.870, p = 0.630). Post-intervention triceps skinfold thickness was significantly greater in the Intervention group (12.29 ± 2.08 mm vs. 11.20 ± 2.40 mm; t = −3.087, p = 0.002), with comparable baselines (9.97 ± 2.10 mm vs. 9.82 ± 2.21 mm; t = −0.448, p = 0.655). Similarly, post-intervention mid-upper arm circumference was significantly higher in the Intervention group (21.11 ± 1.47 cm vs. 19.86 ± 1.65 cm; t = −5.068, p < 0.001), with comparable baseline values (17.15 ± 1.22 cm vs. 16.99 ± 1.37 cm; t = −0.762, p = 0.447). Post-intervention NRS2002 scores were significantly lower in the Intervention group (4.56 ± 0.82 vs. 5.07 ± 0.83; p < 0.001). Moreover, the APACHE II score was significantly lower in the Intervention group (15.06 ± 2.89) than in the Control group (19.85 ± 3.36; t = 9.236, p = 0.000). In the Intervention group, 91.4% of patients achieved ≥70% of energy targets and 88.9% achieved ≥70% of protein targets, compared to 64.2% and 59.3% in the Control group, respectively (both p < 0.001). The Intervention group also had a significantly shorter hospital stay (42.22 ± 7.25 vs. 44.78 ± 5.21 days; p = 0.011). Conclusion: The refined enteral nutrition intervention was associated with improved short-term nutritional status and reduced incidence of feeding intolerance in critically ill stroke patients. However, due to the quasi-experimental design historical controls, the inclusion of adjunctive therapies with unproven efficacy, and the lack of long-term outcome data (including 30-day mortality and functional recovery), categorical claims about improved prognosis cannot be made. The observed benefits may be associated with the comprehensive nursing protocol rather than the refined EN intervention alone and our findings should be interpreted as demonstrating an association rather than a causal relationship. Large-scale, multicenter randomized controlled trials are needed to confirm these findings.
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1860690
Open AccessThe influence of refined enteral nutrition intervention on nutritional status and feeding intolerance in critically ill stroke patients
Background: Critically ill stroke patients frequently experience dysphagia, posing challenges to adequate nutrient intake. Furthermore, these patients often remain in a prolonged state of high stress, hypermetabolism, and reduced immunity. While early enteral nutritional support is crucial, feeding intolerance remains a prevalent issue. This study evaluates the real-world impact of a refined enteral nutrition (EN) intervention on EN outcomes. Objective: To investigate the effect of a refined enteral nutrition intervention on nutritional status and feeding intolerance in critically ill stroke patients. Methods: This quasi-experimental study employed a pre-post design. The control group ( n = 81; January–December 2022) was retrospectively enrolled, and the intervention group ( n = 81; January–December 2023) was prospectively enrolled. The Control group received routine nutrition management, and the Intervention group received refined enteral nutrition management. Primary outcomes assessed included: (1) Nutritional markers: Serum albumin, hemoglobin, triceps skinfold thickness (non-paralyzed side), mid-upper arm circumference (non-paralyzed side); (2) EN intolerance incidence: Diarrhea (≥3 stools/day), vomiting, abdominal distension, elevated gastric residual volume (≥250 mL); (3) Disease severity: APACHE II score. Energy and protein targets were calculated individually (25–30 kcal/kg/day and 1.2–2.0 g/kg/day). Achievement of ≥70% of both targets was considered adequate. (4) Nutritional Risk Screening (NRS2002) and hospital length of stay were also recorded. Results: Post-intervention albumin levels were significantly higher in the Intervention group (40.69 ± 1.88 g/L) compared to the Control group (38.92 ± 1.21 g/L; t = −7.147, p < 0.001), mean difference 1.77 g/L [95% CI: 1.29–2.25], Cohen’s d = 1.12, with comparable baseline values (36.97 ± 2.34 vs. 36.81 ± 1.67 g/L; p = 0.056). Post-intervention hemoglobin levels were also significantly higher in the Intervention group (114.40 ± 8.00 g/L vs. 110.57 ± 6.52 g/L; t = −3.337, p = 0.001), despite comparable baseline values (97.37 ± 9.89 vs. 99.77 ± 5.92 g/L; t = 1.870, p = 0.630). Post-intervention triceps skinfold thickness was significantly greater in the Intervention group (12.29 ± 2.08 mm vs. 11.20 ± 2.40 mm; t = −3.087, p = 0.002), with comparable baselines (9.97 ± 2.10 mm vs. 9.82 ± 2.21 mm; t = −0.448, p = 0.655). Similarly, post-intervention mid-upper arm circumference was significantly higher in the Intervention group (21.11 ± 1.47 cm vs. 19.86 ± 1.65 cm; t = −5.068, p < 0.001), with comparable baseline values (17.15 ± 1.22 cm vs. 16.99 ± 1.37 cm; t = −0.762, p = 0.447). Post-intervention NRS2002 scores were significantly lower in the Intervention group (4.56 ± 0.82 vs. 5.07 ± 0.83; p < 0.001). Moreover, the APACHE II score was significantly lower in the Intervention group (15.06 ± 2.89) than in the Control group (19.85 ± 3.36; t = 9.236, p = 0.000). In the Intervention group, 91.4% of patients achieved ≥70% of energy targets and 88.9% achieved ≥70% of protein targets, compared to 64.2% and 59.3% in the Control group, respectively (both p < 0.001). The Intervention group also had a significantly shorter hospital stay (42.22 ± 7.25 vs. 44.78 ± 5.21 days; p = 0.011). Conclusion: The refined enteral nutrition intervention was associated with improved short-term nutritional status and reduced incidence of feeding intolerance in critically ill stroke patients. However, due to the quasi-experimental design historical controls, the inclusion of adjunctive therapies with unproven efficacy, and the lack of long-term outcome data (including 30-day mortality and functional recovery), categorical claims about improved prognosis cannot be made. The observed benefits may be associated with the comprehensive nursing protocol rather than the refined EN intervention alone and our findings should be interpreted as demonstrating an association rather than a causal relationship. Large-scale, multicenter randomized controlled trials are needed to confirm these findings.
- Open Access
- 21 July 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1834301
Effects of Kuanxiong aerosol for preventing acute mountain sickness: an exploratory small-sample randomized, placebo-controlled trial
Background: This study aimed to evaluate the potential efficacy and neurophysiological effects of Kuanxiong Aerosol (KXA) in preventing acute mountain sickness (AMS) during simulated high-altitude exposure. Methods: In this randomized, double-blind, placebo-controlled trial, 20 healthy volunteers underwent a 6-hour hypobaric hypoxia session (simulated 4000 m) after receiving either KXA or placebo. Outcomes included the Lake Louise Score (LLS), AMS incidence, physiological parameters (SpO 2 , heart rate), cognitive performance (PMT, Symbol-Digit Modalities Test), and cerebral blood flow (CBF) measured by MRI. An exploratory post-hoc subgroup analysis was also conducted in nine participants who voluntarily received an additional KXA session in a self-controlled manner. Results: In the main trial, KXA administration was associated with a non-significant reduction in total LLS and a decrease in AMS incidence from 50% (placebo) to 30% (KXA). No significant differences were observed in SpO 2 , cognitive tests, or global CBF. However, the KXA group showed a smaller increase and more stable heart rate profile over time. Exploratory regional CBF analyses revealed reduced perfusion in selected subregions of the limbic and control networks in the KXA group ( p < 0.05 uncorrected). In the post-hoc self-controlled subgroup (n = 9), KXA significantly reduced total LLS ( p = 0.037) and decreased AMS incidence from 44% to 0%, with trends toward improved cognitive performance. Conclusion: KXA shows preliminary potential for alleviating AMS symptoms under simulated high-altitude conditions, possibly through cardiac and regional cerebrovascular modulation. These findings support further investigation in larger, randomized controlled trials in real-world high-altitude settings to confirm efficacy and clarify the underlying mechanisms. Chinese clinical trial registry: ChiCTR2500105469.
- 21 July 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1834301
Open AccessEffects of Kuanxiong aerosol for preventing acute mountain sickness: an exploratory small-sample randomized, placebo-controlled trial
Background: This study aimed to evaluate the potential efficacy and neurophysiological effects of Kuanxiong Aerosol (KXA) in preventing acute mountain sickness (AMS) during simulated high-altitude exposure. Methods: In this randomized, double-blind, placebo-controlled trial, 20 healthy volunteers underwent a 6-hour hypobaric hypoxia session (simulated 4000 m) after receiving either KXA or placebo. Outcomes included the Lake Louise Score (LLS), AMS incidence, physiological parameters (SpO 2 , heart rate), cognitive performance (PMT, Symbol-Digit Modalities Test), and cerebral blood flow (CBF) measured by MRI. An exploratory post-hoc subgroup analysis was also conducted in nine participants who voluntarily received an additional KXA session in a self-controlled manner. Results: In the main trial, KXA administration was associated with a non-significant reduction in total LLS and a decrease in AMS incidence from 50% (placebo) to 30% (KXA). No significant differences were observed in SpO 2 , cognitive tests, or global CBF. However, the KXA group showed a smaller increase and more stable heart rate profile over time. Exploratory regional CBF analyses revealed reduced perfusion in selected subregions of the limbic and control networks in the KXA group ( p < 0.05 uncorrected). In the post-hoc self-controlled subgroup (n = 9), KXA significantly reduced total LLS ( p = 0.037) and decreased AMS incidence from 44% to 0%, with trends toward improved cognitive performance. Conclusion: KXA shows preliminary potential for alleviating AMS symptoms under simulated high-altitude conditions, possibly through cardiac and regional cerebrovascular modulation. These findings support further investigation in larger, randomized controlled trials in real-world high-altitude settings to confirm efficacy and clarify the underlying mechanisms. Chinese clinical trial registry: ChiCTR2500105469.
- Open Access
- 12 May 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (9) , e70301
Perioperative Normobaric Hyperoxia Combined With Pulmonary Rehabilitation Intervention for Enhanced Short‐Term Recovery in Lung Cancer Surgery
Background: Optimizing perioperative management strategies to promote the rapid recovery remains a focus and challenge research. Normobaric hyperoxia enhances antioxidant defenses and promotes tissue repair, improving functional outcomes in stroke patients. This study aimed to investigate the influence of perioperative normobaric hyperoxia combined with pulmonary rehabilitation on video‐assisted thoracoscopic surgery‐treated lung cancer patients. Methods: This trial enrolled 100 patients with pulmonary nodules scheduled for video‐assisted thoracoscopic surgery (VATS). Eligible patients were randomized in a 1:1 ratio into two groups. The primary outcomes were postoperative length of stay (LOS) and total hospitalization costs. Secondary outcomes included incidence of postoperative pulmonary complications (PPCs), postoperative inflammatory indicators, activities of daily living (ADL), perioperative outcomes, and readmission rates within 30 days and 6 months after discharge. Results: Eighty‐four patients completed the study. The intervention group experienced a significantly shorter postoperative LOS (2 days, IQR 1.8 to 3) and lower total hospitalization cost (41 185 RMB, IQR 35094 to 47 028). The intervention group reported better scores of ADL on postoperative (45 points, IQR 33.8 to 55) and discharge (95 points, IQR 90 to 100). But there were no differences in the incidence of PPCs, C‐reactive protein, procalcitonin, perioperative outcomes, and readmission rates within 30 days and 6 months after discharge. Conclusions: Normobaric hyperoxia combined with perioperative pulmonary rehabilitation may reduce postoperative LOS and decreased costs for VATS‐treated lung cancer patients. This approach expected to optimize outcomes and improve rehabilitation for early‐stage lung cancer patients. Trial Registration: The clinical trial was registered on January 17, 2018, with the registration number ChiCTR1800014512
- 12 May 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (9) , e70301
Open AccessPerioperative Normobaric Hyperoxia Combined With Pulmonary Rehabilitation Intervention for Enhanced Short‐Term Recovery in Lung Cancer Surgery
Background: Optimizing perioperative management strategies to promote the rapid recovery remains a focus and challenge research. Normobaric hyperoxia enhances antioxidant defenses and promotes tissue repair, improving functional outcomes in stroke patients. This study aimed to investigate the influence of perioperative normobaric hyperoxia combined with pulmonary rehabilitation on video‐assisted thoracoscopic surgery‐treated lung cancer patients. Methods: This trial enrolled 100 patients with pulmonary nodules scheduled for video‐assisted thoracoscopic surgery (VATS). Eligible patients were randomized in a 1:1 ratio into two groups. The primary outcomes were postoperative length of stay (LOS) and total hospitalization costs. Secondary outcomes included incidence of postoperative pulmonary complications (PPCs), postoperative inflammatory indicators, activities of daily living (ADL), perioperative outcomes, and readmission rates within 30 days and 6 months after discharge. Results: Eighty‐four patients completed the study. The intervention group experienced a significantly shorter postoperative LOS (2 days, IQR 1.8 to 3) and lower total hospitalization cost (41 185 RMB, IQR 35094 to 47 028). The intervention group reported better scores of ADL on postoperative (45 points, IQR 33.8 to 55) and discharge (95 points, IQR 90 to 100). But there were no differences in the incidence of PPCs, C‐reactive protein, procalcitonin, perioperative outcomes, and readmission rates within 30 days and 6 months after discharge. Conclusions: Normobaric hyperoxia combined with perioperative pulmonary rehabilitation may reduce postoperative LOS and decreased costs for VATS‐treated lung cancer patients. This approach expected to optimize outcomes and improve rehabilitation for early‐stage lung cancer patients. Trial Registration: The clinical trial was registered on January 17, 2018, with the registration number ChiCTR1800014512
- Open Access
- 14 April 2026
- Published by Elsevier in Brain Stimulation
- Vol. 19 (3) , 103099
Reclassifying transcranial pulse stimulation as TNUS: Nonlinear mechanics necessitate departure from the ITRUSST framework
- 14 April 2026
- Published by Elsevier in Brain Stimulation
- Vol. 19 (3) , 103099
Open AccessReclassifying transcranial pulse stimulation as TNUS: Nonlinear mechanics necessitate departure from the ITRUSST framework
- Open Access
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1672725
XELOX combined with sintilimab and hyperbaric oxygen therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase Ib/II clinical trial
Background: Gastric and gastroesophageal junction cancer (GC/GEJC) is the fifth most common and deadliest cancers worldwide, with five-year survival rates ranging from 20–40% due to late-stage diagnosis. First-line treatment for HER2-negative advanced or metastatic GC/GEJC involves chemotherapy combined with PD-1 inhibitors, achieving an objective response rate (ORR) of approximately 60%. However, primary and acquired resistance limits effectiveness, highlighting the need for novel strategies. Tumor hypoxia reduces the efficacy of immune checkpoint inhibitors (ICIs). Hyperbaric oxygen therapy (HBOT) may alleviate hypoxia, enhance drug delivery, and improve immune cell infiltration, potentially increasing the antitumor effects of ICIs. Methods: This prospective, single-center, single-arm phase Ib/II trial evaluated the efficacy and safety of the XELOX regimen combined with sintilimab and HBOT in HER2-negative advanced or metastatic GC/GEJC patients. Phase Ib employs a 3 + 3 dose-escalation design with nine patients to assess safety and determine the optimal HBOT protocol. Phase II will enrol 48 patients, accounting for a 5% dropout rate, with a focus on the ORR as the primary endpoint. The secondary endpoints include progression-free survival (PFS), the disease control rate (DCR), 2-year disease free survival (DFS), two-year overall survival (OS), quality of life (QoL), and safety. All participants received XELOX, sintilimab and HBOT. Efficacy is assessed every two cycles, with maintenance therapy continuing until disease progression or other termination criteria are met. Discussion: This is the first clinical trial to explore the efficacy and safety of HBOT combined with chemotherapy and immunotherapy in HER2-negative advanced or metastatic GC/GEJC patients. These results may provide a novel treatment strategy for patients with advanced GC/GEJC, addressing the current limitations of immunotherapy resistance. Clinical Trial Registration: ClinicalTrials.gov , identifier NCT06742411.
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1672725
Open AccessXELOX combined with sintilimab and hyperbaric oxygen therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase Ib/II clinical trial
Background: Gastric and gastroesophageal junction cancer (GC/GEJC) is the fifth most common and deadliest cancers worldwide, with five-year survival rates ranging from 20–40% due to late-stage diagnosis. First-line treatment for HER2-negative advanced or metastatic GC/GEJC involves chemotherapy combined with PD-1 inhibitors, achieving an objective response rate (ORR) of approximately 60%. However, primary and acquired resistance limits effectiveness, highlighting the need for novel strategies. Tumor hypoxia reduces the efficacy of immune checkpoint inhibitors (ICIs). Hyperbaric oxygen therapy (HBOT) may alleviate hypoxia, enhance drug delivery, and improve immune cell infiltration, potentially increasing the antitumor effects of ICIs. Methods: This prospective, single-center, single-arm phase Ib/II trial evaluated the efficacy and safety of the XELOX regimen combined with sintilimab and HBOT in HER2-negative advanced or metastatic GC/GEJC patients. Phase Ib employs a 3 + 3 dose-escalation design with nine patients to assess safety and determine the optimal HBOT protocol. Phase II will enrol 48 patients, accounting for a 5% dropout rate, with a focus on the ORR as the primary endpoint. The secondary endpoints include progression-free survival (PFS), the disease control rate (DCR), 2-year disease free survival (DFS), two-year overall survival (OS), quality of life (QoL), and safety. All participants received XELOX, sintilimab and HBOT. Efficacy is assessed every two cycles, with maintenance therapy continuing until disease progression or other termination criteria are met. Discussion: This is the first clinical trial to explore the efficacy and safety of HBOT combined with chemotherapy and immunotherapy in HER2-negative advanced or metastatic GC/GEJC patients. These results may provide a novel treatment strategy for patients with advanced GC/GEJC, addressing the current limitations of immunotherapy resistance. Clinical Trial Registration: ClinicalTrials.gov , identifier NCT06742411.
- Open Access
- 4 June 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1455545
Bibliometric analysis of research trends on hyperbaric oxygen therapy in stroke from 2000 to 2022
Background: Stroke primarily results from the interruption of cerebral blood flow. Hyperbaric oxygen therapy (HBOT), a noninvasive and promising therapeutic intervention, has been widely used to treat various ischemic and hypoxic conditions. Over the past two decades, extensive research has demonstrated HBOT's efficacy in reducing cerebral infarct volume, establishing it as a viable neuroprotective strategy. Given these findings, this study employs bibliometric analysis to explore emerging trends and key research foci in HBOT applications for stroke management.Method: We performed a systematic literature search on hyperbaric oxygen therapy (HBOT) and stroke using the Web of Science Core Collection (WoSCC) database, specifically the Science Citation Index Expanded (SCI-Expanded). The search was restricted to English-language articles and reviews published between January 2000 and December 2022. Data retrieval, screening, and analysis were conducted in June 2023.Results: A total of 323 publications were identified, demonstrating annual fluctuations in research output. The United States dominated HBOT-related stroke research in both publication volume and scientific impact. Shai Efrati emerged as the most prolific author in this field, while the Sackler Faculty of Medicine at Tel Aviv University was the most influential institution. The journal Stroke published the highest number of HBOT-related stroke studies. Co-citation analysis revealed “cognitive function” as the primary research focus in HBOT applications for stroke.Conclusion: This bibliometric analysis investigated the current research landscape, trends, and emerging priorities in hyperbaric oxygen therapy (HBOT) applications for stroke. The primary research focus centered on HBOT's therapeutic potential for cognitive function enhancement and chronic-phase post-stroke treatment.
- 4 June 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1455545
Open AccessBibliometric analysis of research trends on hyperbaric oxygen therapy in stroke from 2000 to 2022
Background: Stroke primarily results from the interruption of cerebral blood flow. Hyperbaric oxygen therapy (HBOT), a noninvasive and promising therapeutic intervention, has been widely used to treat various ischemic and hypoxic conditions. Over the past two decades, extensive research has demonstrated HBOT's efficacy in reducing cerebral infarct volume, establishing it as a viable neuroprotective strategy. Given these findings, this study employs bibliometric analysis to explore emerging trends and key research foci in HBOT applications for stroke management.Method: We performed a systematic literature search on hyperbaric oxygen therapy (HBOT) and stroke using the Web of Science Core Collection (WoSCC) database, specifically the Science Citation Index Expanded (SCI-Expanded). The search was restricted to English-language articles and reviews published between January 2000 and December 2022. Data retrieval, screening, and analysis were conducted in June 2023.Results: A total of 323 publications were identified, demonstrating annual fluctuations in research output. The United States dominated HBOT-related stroke research in both publication volume and scientific impact. Shai Efrati emerged as the most prolific author in this field, while the Sackler Faculty of Medicine at Tel Aviv University was the most influential institution. The journal Stroke published the highest number of HBOT-related stroke studies. Co-citation analysis revealed “cognitive function” as the primary research focus in HBOT applications for stroke.Conclusion: This bibliometric analysis investigated the current research landscape, trends, and emerging priorities in hyperbaric oxygen therapy (HBOT) applications for stroke. The primary research focus centered on HBOT's therapeutic potential for cognitive function enhancement and chronic-phase post-stroke treatment.
- Open Access
- 30 May 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (22) , e42660
Functional connectivity characteristics of epilepsy with anxiety: A resting-state functional near-infrared spectroscopy study
Functional near-infrared spectroscopy (fNIRS) was applied to investigate the resting-state functional connectivity (RSFC) characteristics of the cerebral cortex in epileptic patients with and without anxiety. A total of 38 epileptic patients were recruited and divided into 2 groups according to the Generalized Anxiety Disorder 7-item score: epilepsy with anxiety (anxiety group) and epilepsy without anxiety (non-anxiety group). Resting-state fNIRS for 15 minutes was performed on each patient. Preprocessing of fNIRS data and RSFC analysis were performed in NirSpark software (Danyang Huichuang Medical Equipment Co., Ltd., China). Brain network was divided into 6 regions of interest (ROI). Based on the concentration of oxygenated hemoglobin in the time series, the RSFC strength was calculated. The RSFC between the 2 groups was compared in the bilateral prefrontal cortex, sensory cortex, and motor cortex. Epileptic patients with anxiety showed a decrease in group-averaged RSFC strength and ROI–ROI connectivity strength. The mean strength of RSFC and its standard deviations were 0.34 ± 0.14 for the anxiety group and 0.38 ± 0.15 for the non-anxiety group (P > .05, t = 0.854). The RSFC between part of the frontal and parietal channels in the anxiety group was significantly lower than that in the non-anxiety group (P < .05, t = 2.897). However, no significant difference was found after false discovery rate (FDR) correction. Before FDR correction, there was no significant difference except for the functional connectivity between the right prefrontal cortex and left motor cortex (P = .046, t = 2.064). However, there was no significant difference after FDR correction. fNIRS is an available imaging instrument for examining RSFC in various contexts. In this specific investigation, no significant difference was found in functional connectivity between epileptic patients with or without anxiety using resting-state fNIRS. Future studies should consider employing larger sample sizes or utilizing task-state fNIRS methodologies. By continuing to explore the capabilities of fNIRS in understanding brain connectivity and its association with anxiety in epilepsy patients, we can provide information for more effective diagnostic and therapeutic approaches, ultimately enhancing the care and management of these individuals.
- 30 May 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (22) , e42660
Open AccessFunctional connectivity characteristics of epilepsy with anxiety: A resting-state functional near-infrared spectroscopy study
Functional near-infrared spectroscopy (fNIRS) was applied to investigate the resting-state functional connectivity (RSFC) characteristics of the cerebral cortex in epileptic patients with and without anxiety. A total of 38 epileptic patients were recruited and divided into 2 groups according to the Generalized Anxiety Disorder 7-item score: epilepsy with anxiety (anxiety group) and epilepsy without anxiety (non-anxiety group). Resting-state fNIRS for 15 minutes was performed on each patient. Preprocessing of fNIRS data and RSFC analysis were performed in NirSpark software (Danyang Huichuang Medical Equipment Co., Ltd., China). Brain network was divided into 6 regions of interest (ROI). Based on the concentration of oxygenated hemoglobin in the time series, the RSFC strength was calculated. The RSFC between the 2 groups was compared in the bilateral prefrontal cortex, sensory cortex, and motor cortex. Epileptic patients with anxiety showed a decrease in group-averaged RSFC strength and ROI–ROI connectivity strength. The mean strength of RSFC and its standard deviations were 0.34 ± 0.14 for the anxiety group and 0.38 ± 0.15 for the non-anxiety group (P > .05, t = 0.854). The RSFC between part of the frontal and parietal channels in the anxiety group was significantly lower than that in the non-anxiety group (P < .05, t = 2.897). However, no significant difference was found after false discovery rate (FDR) correction. Before FDR correction, there was no significant difference except for the functional connectivity between the right prefrontal cortex and left motor cortex (P = .046, t = 2.064). However, there was no significant difference after FDR correction. fNIRS is an available imaging instrument for examining RSFC in various contexts. In this specific investigation, no significant difference was found in functional connectivity between epileptic patients with or without anxiety using resting-state fNIRS. Future studies should consider employing larger sample sizes or utilizing task-state fNIRS methodologies. By continuing to explore the capabilities of fNIRS in understanding brain connectivity and its association with anxiety in epilepsy patients, we can provide information for more effective diagnostic and therapeutic approaches, ultimately enhancing the care and management of these individuals.
- Open Access
- 17 July 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1399600
Research trends and hotspots for frontotemporal dementia from 2000 to 2022: a bibliometric analysis
Background: Frontotemporal dementia (FTD) is a neurodegenerative disease with clinical, pathological, and genetic heterogeneity. FTD is receiving increasing attention because it is the second leading cause of early-onset dementia after Alzheimer’s disease. This study aimed to analyse the research trends and hotspots of FTD from 2000 to 2022 using bibliometrics.Methods: Papers related to FTD from 2000 to 2020 were systematically searched through the Web of Science Core Collection (WOSCC). Citespace and Vosviewer software were used to visually analyse the retrieved data of countries/regions, institutions, journals, authors, references, and keywords. Microsoft Excel was used to generate the annual publications and growth trends.Results: There were 10,227 papers included in the bibliometric analysis. The annual publication output on FTD has increased significantly from 2000 to 2022, with papers published in 934 academic journals and 87 countries/regions. The Journal of Alzheimer’s Disease was the most popular, with 488 papers about FTD. The most productive countries/regions, institutions, and authors are the United States (n = 4,037), the University of California San Francisco (n = 687), and Miller, Bruce L. (n = 427), respectively. The article by Katya Rascovsky and her colleagues published on Brain in 2011 was the most cocited paper, with 625 citations. The research hotspots in this field were the clinical diagnostic criteria, subdivision, and pathological mechanism of FTD, such as tau protein, chromosome 17, progranulin, TDP-43, and C9orf72.Conclusion: The future research direction is based on biomarkers and pathological mechanisms to diagnose and differential diagnose FTD from the aspects of behavior, neuropathology, neuroimaging, and serum markers.
- 17 July 2024
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1399600
Open AccessResearch trends and hotspots for frontotemporal dementia from 2000 to 2022: a bibliometric analysis
Background: Frontotemporal dementia (FTD) is a neurodegenerative disease with clinical, pathological, and genetic heterogeneity. FTD is receiving increasing attention because it is the second leading cause of early-onset dementia after Alzheimer’s disease. This study aimed to analyse the research trends and hotspots of FTD from 2000 to 2022 using bibliometrics.Methods: Papers related to FTD from 2000 to 2020 were systematically searched through the Web of Science Core Collection (WOSCC). Citespace and Vosviewer software were used to visually analyse the retrieved data of countries/regions, institutions, journals, authors, references, and keywords. Microsoft Excel was used to generate the annual publications and growth trends.Results: There were 10,227 papers included in the bibliometric analysis. The annual publication output on FTD has increased significantly from 2000 to 2022, with papers published in 934 academic journals and 87 countries/regions. The Journal of Alzheimer’s Disease was the most popular, with 488 papers about FTD. The most productive countries/regions, institutions, and authors are the United States (n = 4,037), the University of California San Francisco (n = 687), and Miller, Bruce L. (n = 427), respectively. The article by Katya Rascovsky and her colleagues published on Brain in 2011 was the most cocited paper, with 625 citations. The research hotspots in this field were the clinical diagnostic criteria, subdivision, and pathological mechanism of FTD, such as tau protein, chromosome 17, progranulin, TDP-43, and C9orf72.Conclusion: The future research direction is based on biomarkers and pathological mechanisms to diagnose and differential diagnose FTD from the aspects of behavior, neuropathology, neuroimaging, and serum markers.
- Open Access
- 17 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (46) , e36111
Published trends and research hotspots of central venous catheter-associated thrombosis from 1973 to 2022: A scientometric analysis
This study aims to explore the intellectual landscape and research hotspots in the central venous catheter-related thrombosis (CVC-RT) research field. Studies discussing CVC-RT published from 1973 to 2022 in the Web of Science Core Collection database were retrieved on February 24th, 2022. Citespace was used to perform a scientometric analysis to identify the intellectual landscape and research hotspots in the research fields of CVC-RT. A total of 4358 studies were retrieved, with an ascending trend in publication numbers. The United States of America was the most influential country. The Journal of Vascular Access published the most studies, and McMaster University was the most prolific institution. The results showed that the focus population of CVC-RT research has changed from pediatric patients to cancer patients, the management of CVC-RT has become more formal and standardized, and the focused CVC type has shifted to port and peripherally inserted central catheters. In addition, seventeen active burst keywords were detected, such as patient safety, clinical practice guidelines, and postthrombotic syndrome. This study comprehensively reviewed publications related to CVC-RT. The research topics on patient safety, clinical practice guidelines, and postthrombotic syndrome related to CVC-RT may be future hotspots.
- 17 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (46) , e36111
Open AccessPublished trends and research hotspots of central venous catheter-associated thrombosis from 1973 to 2022: A scientometric analysis
This study aims to explore the intellectual landscape and research hotspots in the central venous catheter-related thrombosis (CVC-RT) research field. Studies discussing CVC-RT published from 1973 to 2022 in the Web of Science Core Collection database were retrieved on February 24th, 2022. Citespace was used to perform a scientometric analysis to identify the intellectual landscape and research hotspots in the research fields of CVC-RT. A total of 4358 studies were retrieved, with an ascending trend in publication numbers. The United States of America was the most influential country. The Journal of Vascular Access published the most studies, and McMaster University was the most prolific institution. The results showed that the focus population of CVC-RT research has changed from pediatric patients to cancer patients, the management of CVC-RT has become more formal and standardized, and the focused CVC type has shifted to port and peripherally inserted central catheters. In addition, seventeen active burst keywords were detected, such as patient safety, clinical practice guidelines, and postthrombotic syndrome. This study comprehensively reviewed publications related to CVC-RT. The research topics on patient safety, clinical practice guidelines, and postthrombotic syndrome related to CVC-RT may be future hotspots.